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DECISION
Subject: Memorandum of Understanding for the implementation of the COST Action
“European Network to Advance Best practices & technoLogy on medication
adherencE” (ENABLE) CA19132
The COST Member Countries and/or the COST Cooperating State will find attached the Memorandum of
Understanding for the COST Action European Network to Advance Best practices & technoLogy on
medication adherencE approved by the Committee of Senior Officials through written procedure on 24
March 2020.
MEMORANDUM OF UNDERSTANDING
For the implementation of a COST Action designated as
COST Action CA19132
EUROPEAN NETWORK TO ADVANCE BEST PRACTICES & TECHNOLOGY ON MEDICATION
ADHERENCE (ENABLE)
The COST Member Countries and/or the COST Cooperating State, accepting the present Memorandum of
Understanding (MoU) wish to undertake joint activities of mutual interest and declare their common
intention to participate in the COST Action (the Action), referred to above and described in the Technical
Annex of this MoU.
The Action will be carried out in accordance with the set of COST Implementation Rules approved by the
Committee of Senior Officials (CSO), or any new document amending or replacing them:
a.  “Rules for Participation in and Implementation of COST Activities” (COST 132/14 REV2);
b.  “COST Action Proposal Submission, Evaluation, Selection and Approval” (COST 133/14 REV);
c.  “COST Action Management, Monitoring and Final Assessment” (COST 134/14 REV2);
d.  “COST International Cooperation and Specific Organisations Participation” (COST 135/14 REV).
The main aim and objective of the Action is to create a multidisciplinary network of relevant stakeholders
that work collaboratively towards economically viable implementation of medication adherence enhancing
technologies across different European healthcare systems. This will be achieved through the specific
objectives detailed in the Technical Annex.
The economic dimension of the activities carried out under the Action has been estimated, on the basis of
information available during the planning of the Action, at EUR 88 million in 2019.
The MoU will enter into force once at least seven (7) COST Member Countries and/or COST Cooperating
State have accepted it, and the corresponding Management Committee Members have been appointed, as
described in the CSO Decision COST 134/14 REV2.
The COST Action will start from the date of the first Management Committee meeting and shall be
implemented for a period of four (4) years, unless an extension is approved by the CSO following the





Due to an ageing society, there is a steady increase in chronic diseases and multi-morbidity in Europe. This
rise of chronic diseases and multi-morbidity requires a multidisciplinary response, which often involves
lifestyle changes combined with lifetime medication use.
Medication non-adherence affects however up to half of the chronic medication users, poses considerable
challenges in managing chronic diseases, and is associated with almost 200,000 deaths and €80-125 billion
of potentially preventable direct and indirect costs in Europe. Technological advances (e.g. smart pillboxes,
digital inhalers, tracking devices, e-injection pens, e-Health, big data), have significant potential to support
healthcare professionals and empower patients in detecting and managing non-adherence.
Awareness of healthcare professionals on the availability and implementation of adherence enhancing
technology is limited and there is a lack of collaboration between stakeholders. Successful European-wide
implementation of adherence enhancing technology is further hampered by a lack of insight in different
European healthcare systems, reimbursement pathways and policy regulations that significantly differ
between countries. This affects not only patients and healthcare professionals, but also manufacturers of
technology (mostly SMEs) in their innovation capacity and competitiveness.
To address these challenges, the European Network to Advance Best practices & technoLogy on medication
adherencE (ENABLE) aims to (1) raise awareness of adherence enhancing technological solutions, (2) foster
and extend multidisciplinary knowledge on medication adherence at patient, treatment and system levels, (3)
accelerate translation of this knowledge to useful clinical application and (4) work collaboratively towards
economically viable implementation of adherence enhancing technology across European healthcare
systems.
Areas of Expertise Relevant for the Action
● Health Sciences: Health services, health care research
● Clinical medicine: General and internal medicine
● Medical engineering: Medical engineering and technology
● Health Sciences: Nursing
● Basic medicine: Pharmacology, pharmacogenomics, drug








To achieve the main objective described in this MoU, the following specific objectives shall be
accomplished:
Research Coordination
● Benchmark, assess and raise awareness on current practices on tackling non-adherence in different
healthcare settings across Europe. This entails the exchange of best practices, facilitators/barriers,
experiences and expertise of different healthcare providers (GPs, specialists, pharmacists, nurses, health
psychologists) and patients in dealing with non-adherence issues in daily life and practice.
● Accelerate the availability and implementation of adherence enhancing technologies across Europe.
This entails the exchange (e.g. through webplatforms, social media) of multidisciplinary knowledge and
creates awareness among healthcare providers on the availability and potential of innovative adherence
measurement methods and adherence enhancing technology for clinical practice.
● Gather expert input for future market applications and implementation of cutting-edge adherence
enhancing technology. Knowledge exchange on cost-effectiveness, patient access pathways, and
reimbursement could help the implementation.
3
Capacity Building
● Bringing together currently isolated stakeholders and building up a network to achieve breakthroughs in
the development of new process to advance the implementation of adherence enhancing technologies.
This will be achieved by hosting meetings, workshops and conferences.
● Developing a platform to exchange and foster adherence knowledge, including a repository of best
practices and technologies that can enhance medication adherence. Per intervention, an independent
assessment of its effectiveness and cost-effectiveness will be provided by a panel of multidisciplinary
experts.
● Translate and disseminate knowledge on technologies to specific target groups such as Early Career
Investigators (ECIs) and researchers from less research-intensive countries. This will be achieved by
hosting meetings and workshops, organizing Training Schools and opportunities for Short-Term Scientific
Missions (STSMs).

















1 S&T EXCELLENCE 
1.1 SOUNDNESS OF THE CHALLENGE  
1.1.1 DESCRIPTION OF THE STATE-OF-THE-ART 
In 2003, the influential World Health Organization (WHO) report “Adherence to long-term therapies: 
evidence for action” was published.1 This report was based on an exhaustive literature review on 
adherence definitions, measurements, epidemiology, economics and interventions applied to nine 
chronic conditions and risk factors. It highlighted the scope of the problem (only 50% of patients adhere 
to long-term therapy) as well as the significant consequences for health and economics. It stimulated 
new thinking on policy development and action to improve adherence to long-term therapies. 
 
In the years that followed, a wealth of studies provided new insights into the different reasons for 
nonadherence. Notably, these can be situated at the patient level (e.g. beliefs, cognition, comorbidities, 
knowledge), at the treatment level (e.g. side effects, dosing regimen, co-medication) and/or at the 
system level (access to medication, relationship with healthcare providers, social support). 
 
Within an individual patient, one or more of these reasons could result in three main types of 
nonadherence (WHO definitions). Two of these are also characterized as unintentional and include 
erratic non-adherence (i.e. forgetfulness) and unwitting non-adherence (i.e. lack of knowledge). In the 
case of intentional non-adherence at personal level, a patient deliberately alters or discontinues 
prescribed therapy due to a conscious decision, such as lack of necessity or fear of side effect or high 
costs.1 In addition, many studies have focused on estimating specific rates of adherence across different 
(chronic) diseases (e.g. asthma, diabetes), medications (e.g. inhaled corticosteroids, metformin), patient 
populations (e.g. elderly, adolescents) and geographical areas (e.g. urban, areas with high/low 
socioeconomic status). These studies show profound differences between studied groups (e.g. a higher 
number of medications per patient was associated with higher non-adherence rates). Over the past 
decades, the inconsistent use of adherence definitions has hampered fair cross-study comparison 
however since 2012, consensus has been reached that the adherence process consists of three 
distinctive phases including initiation, implementation and persistence.2 
 
To enhance adherence, multiple intervention strategies have been tested with varying results. 
Notably, most studies took one-size-fits-all approaches and did not select patients based on the 
underlying causes of non-adherence. In addition, interventions were usually applied once, thereby 
neglecting the chronic nature of adherence. Due to better understanding of underlying reasons for 
nonadherence, it has become increasingly clear that a one-size-fits-all approach is likely to fail. In 
addition, it is now recognised that there exists an interplay between medication adherence and lifestyle 
change, in chronic diseases. This may implicate that the two phenomena should be addressed together 
and interventions may best work when technological and behavioural strategies are combined. 
 
A personalized approach may be the way forward in tackling non-adherence, particularly if solutions are 
based on the type of non-adherence in question and its underlying causes. For example, patients with 
erratic non-adherence may benefit from reminders; patients with unintentional non-adherence may need 
support in habit formation, while patients with intentional non-adherence would benefit from education, 
motivational interviewing, reimbursement or shared decision making processes.2 
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In current clinical practice, healthcare providers are short of knowledge and insights on how to monitor 
adherence and apply the appropriate interventions for individual patients. In addition, patients are 
insufficiently empowered and lack tools to self-monitor, self-manage and optimize their drug use. In 
particular when embedded in existing behavioural change frameworks and combined with proper 
communication strategies, new technology may assist both patients and healthcare providers in 
managing non-adherence on a continuous basis instead of the current one-time interventions.  
1.1.2 DESCRIPTION OF THE CHALLENGE (MAIN AIM) 
Mainly due to an ageing society, there is a steady increase in chronic diseases and multi-morbidity in 
Europe. The rise of chronic diseases and multi-morbidity requires a multidisciplinary response, which 
often involves lifestyle changes and lifetime medication use. Despite the availability of many effective 
drugs, it has been estimated that medication non-adherence is associated with almost 200,000 
deaths and €80-125 billion of potentially preventable direct (e.g. hospitalizations, waste of medication) 
and indirect (e.g. work productivity losses) costs in the European Union (EU) alone.3 Unfortunately, 
medication non-adherence affects, depending on definitions used, up to 20-50% of patients that use 
chronic medication.1 Moreover, in the last decades, there has been little improvement in adherence 
across the spectrum of multiple chronic diseases. Notably, data show profound variance in adherence 
within- and between- countries. In line with other factors that may affect adherence, e.g. low socio-
economic status4, this suggests inequitable implementation of adherence enhancing solutions. This is 
one of the reasons the WHO has qualified medical adherence as a key indicator for quality of care.5 
 
Recently developed technological advances (e.g. smart pill-boxes/packaging, digital inhalers, audio 
and vibration-based tracking devices, pill-tracers and e-injection pens, e-Health self-management 
applications, big data) can greatly support healthcare professionals and empower patients in detecting 
and managing non-adherence. However, currently the application of these innovative technologies is 
still mainly limited to clinical trial settings, thereby not reaching the healthcare professionals and 
patients in real-life practice. In addition, awareness of healthcare professionals on the availability and 
implementation of adherence enhancing technology is limited, the technology is usually not embedded 
in a broader understanding of the reasons for suboptimal adherence and there is a lack of collaboration 
between key stakeholders to jointly work towards shared implementation goals.6 Moreover, the 
successful European-wide implementation of innovative adherence enhancing technology in daily 
practice, is further hampered by a lack of insight in the different European healthcare systems, 
reimbursement pathways and policy regulations that significantly differ from country to country. 
 
Most of the recent innovations in adherence enhancing technology derives from the medical device 
industry, represented by about 25,000 companies of which the vast majority (+/-95%) small and 
medium-sized enterprises (SMEs). Besides being the main employer of 575,000 people in the EU, these 
SMEs are responsible for €100 billion of sales.7 Yet, SMEs in particular face many challenges 
at national, European  
and international levels which affects their innovation capacity and competitiveness. Notably, only 7% 
of SMEs in the EU sell cross-borders, a reason for which the EU has promoted the Digital Single Market 
strategy.8 Main challenges are related to bridging the gap between the technological innovation being 
developed and validated and their sustainable implementation in daily clinical practice. In particular, for 
SMEs it is of utmost importance to provide patients and providers with early access to their technology 
whilst simultaneously ensuring that reimbursement is in place across healthcare systems in Europe and 
further around the globe. 
 
In summary, there is a rich foundation of knowledge on medication (non) adherence, its societal impact, 
adherence enhancing interventions, and the potential of technological solutions. Nevertheless, 
the compilation and translation of this knowledge into practice is lacking. Stakeholders are inadequately 
informed about non-adherence and the availability of technological solutions, and collaborative efforts 
to push forward their implementation are scarce. 
 
The overarching objective of the European Network to Advance Best practices & technoLogy on 
medication adherencE (ENABLE) is to create a network of relevant stakeholders that (1) raise 
awareness of adherence enhancing solutions, (2) foster and extend multidisciplinary knowledge 
on medication adherence at patient, treatment and system levels, (3) accelerate translation of this 
knowledge from producers to useful clinical application and (4) work collaboratively towards 
economically viable implementation of adherence enhancing technology across different European 
healthcare systems. 
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1.2 PROGRESS BEYOND THE STATE-OF-THE-ART  
1.2.1 APPROACH TO THE CHALLENGE AND PROGRESS BEYOND THE STATE-OF-THE-ART 
ENABLE will establish a knowledge base beyond the current state of play, and actively engage the 
private sector to foster innovative technology based solutions to tackle non-adherence. 
 
In order to select the right interventions for the needs of individual patients (i.e. personalized medicine), 
in-depth insights into longitudinal patterns of drug utilization are required. This could be accomplished 
by digitally engaging healthcare providers with patients for optimal monitoring and timely interventions 
in the process of adherence. 
 
It is important to note that the management of adherence is not pushing for more pills taken, but rather 
to reach an optimal treatment exposure for each patient. This can only be achieved if reliable and 
detailed adherence data are integrated in the healthcare system. Currently, several companies, mostly 
SMEs, are in advanced stages of developing innovative adherence enhancing technology such as 
inhalers based on acoustic sound or vibration-based technology to track frequency and quality of use, 
electronic pill blisters, linked real-life patient medication records, self-management support apps with 
wearable reminders, movement based injectables and digital tracers. 
 
Despite the multitude of examples of great technological innovation, true progress can only be made if 
stakeholders work together towards sustainable implementation, which requires the involvement of 
stakeholders throughout the development process. 
 
A recent example is the co-application at the United States Food and Drug Administration (FDA) of a 
drug manufacturer and a technology SME with an ingestible sensor embedded in a tablet that can 
measure adherence and other vital functions which communicates through digital platforms to be used 
by patients and in healthcare provider-patient interactions.9 This example is the result of early 
engagement of all relevant stakeholders, but is still not or very rarely seen in European markets. 
 
In order to successfully implement 
non-adherence technologies, 
stakeholders in multiple levels of the 
healthcare system need to be 
prepared to accept and employ these 
solutions. ENABLE will serve as a 
stepping stone towards the ultimate 
goal of achieving full integration of 
healthcare provider insights, patient 
education and empowerment, and 
digital adherence management 
technology within a sustainable 
healthcare system that is ready to 
receive it, both clinically and 
economically (Figure 1). 
 
Figure 1: Integration of healthcare provider insights, patient empowerment and technology in a 
sustainable system 
 
More concretely, ENABLE will promote the establishment of unique local “medication adherence 
expertise centers” where multidisciplinary knowledge is combined on a regional or national level. 
Notably, these centers will not only serve as a knowledge hubs, but could also provide educational 
courses and play important roles as implementation platforms for effective interventions. 
 
Approach to the challenge 
 
By connecting cutting-edge adherence enhancing technology engineers with a range of healthcare 
stakeholders (i.e. providers, patients, as well as payers) the ENABLE network works towards a fully 
integrated and individualized adherence strategy. Given the scope of the problem and because 
SMEs may aim to work across the borders of a country, ENABLE aims to create a multidisciplinary 
network of as many European countries as possible. Within each country, representatives of different 
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key stakeholders will be identified on a continuous basis and added to the previously mentioned local 
“medication adherence expertise centers”. The first Action general meeting will be organized at a central 
European location in which the main challenges of ENABLE will be outlined and presented to the 
multidisciplinary audience. The main session will be followed by smaller scale break-out sessions where 
specific issues will be discussed and presented in the subsequent plenary session. The medication 
adherence expertise centers will continue their collaboration by sharing their experiences with 
adherence technology, health care practice and healthcare systems on a freely-accessible web 
platform with country/setting specific information to guide optimal implementation of adherence 
enhancing technology. Beyond the COST Action and the web-platform, expertise center representatives 
are also foreseen to keep on meeting at designated annual adherence conferences such as those 
organized by the European adherence society ESPACOMP. The ultimate goal is not to create new 
technology (though innovative technologies will be rapidly adopted as they emerge), but to create a new 
process to stimulate early & easy access of technology to providers and patients and to make use 
of the existing technology in the most cost-effective way. In that sense, the true innovation lies in the 
collaboration of stakeholders who usually do not work together. Through engaging and connecting 
stakeholders ENABLE will benchmark current practice, explore their potential for scalability and 
eventually fuel the sustainable implementation of technology across diverse European healthcare 
systems, to create impact within both health & socio-economic settings. 
1.2.2 OBJECTIVES 
1.2.2.1 Research Coordination Objectives 
In order to tackle the challenges related to implementing solutions to reduce medication non-adherence, 
three research coordination objectives have been formulated to stimulate private-public networking and 
cutting-edge collaborative and multidisciplinary research: 
 
1. Benchmark, assess and raise awareness on current practices on tackling non-adherence in 
different healthcare settings across Europe. This entails the exchange of best practices, 
facilitators/barriers, experiences and expertise of different healthcare providers (GPs, specialists, 
pharmacists, nurses, health psychologists) and patients in dealing with non-adherence issues in daily 
life and practice. 
 
2. Accelerate the availability and implementation of adherence enhancing technologies across 
Europe.This entails the exchange (e.g. through webplatforms, vlogs, social media) of multidisciplinary 
knowledge and creates awareness among healthcare providers on the availability and potential of 
innovative adherence measurement methods and adherence enhancing technology (electronic 
monitoring, eHealth apps & tools) for clinical practice. 
 
3. Gather expert input for future market applications and implementation of cutting-edge 
adherence enhancing technology as developed by small and medium size enterprises (SMEs). Many 
technologies have large potential, but may fail when they are not fit for a healthcare system that is not 
ready to receive it. In addition, SMEs’ innovations may fail if they do not embed their technology in the 
broader context of behaviour change. Knowledge exchange on cost-effectiveness, patient access 
pathways, pricing, reimbursement and permanent integration of innovative adherence interventions in 
different European healthcare systems and clinical guidelines could help to overcome this hurdle and 
better prepare new technologies for smooth patient access and integration in existing systems. 
1.2.2.2 Capacity-building Objectives 
1. Bringing together currently isolated stakeholders and building up a network to achieve 
breakthroughs in the development of new process to advance the implementation of adherence 
enhancing technologies. This will be achieved by hosting meetings, workshops and conferences. 
 
2. Developing a platform and trans-national practice & policy community to exchange and foster 
knowledge. To achieve this, a web platform will be compiled and hosted which will include a repository 
of best practices and technologies that can enhance medication adherence and examples of successful 
implementation and patient access pathways. Per intervention, an independent assessment of its 
effectiveness and cost-effectiveness will be provided by a panel of multidisciplinary experts not having 
a conflict of interest. Industry (pharmaceutical, IT) may propose an intervention to be included on the 
platform but cannot provide the aforementioned assessment. 
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3. Translate and disseminate knowledge on technologies to specific target groups such as PhD 
students, Early Career Investigators (ECIs, defined as PhD + up to 8 years) and researchers from less 
research-intensive countries. This will be achieved by hosting meetings and workshops, organizing 
Training Schools and opportunities for Short-Term Scientific Missions (STSMs). Through these STSMs, 
the specific target groups can learn from experienced investigators and policy makers on the use and 
regulations of technology in other countries. Alternatively, they can learn directly from engineers at 
SMEs that are developing these adherence enhancing technologies or from regulatory policy makers 
that are assessing these technologies. At the same time, the researchers’ clinical and academic 
experience and country-specific knowledge could benefit the SMEs in further optimizing their 
technologies to make them fit for purpose. 
2 NETWORKING EXCELLENCE 
2.1 ADDED VALUE OF NETWORKING IN S&T EXCELLENCE 
2.1.1 ADDED VALUE IN RELATION TO EXISTING EFFORTS AT EUROPEAN AND/OR 
INTERNATIONAL LEVEL 
Through the ENABLE network, stakeholders are able to collaborate and work towards a mutual 
objective: sustainable implementation of adherence enhancing solutions in order to improve patient 
outcomes and decrease total healthcare costs. Close and early collaboration with national action plan 
leaders (e.g. through focus groups and round-table processes), patient groups as well as decision 
makers will be sought to optimally leverage national research investments. 
 
Networking is not only necessary within countries and between national stakeholders, but especially 
between countries. Notably, much of the current knowledge is centered in Western European research 
settings, while the transfer of this knowledge (to e.g. Eastern Europe) lags behind, resulting in 
unequal access to promising technology and best practices. Of note, challenges related to 
nonadherence are very similar between countries and sharing knowledge will enable the early access 
to best practices and prevent unnecessary reinventing of the wheel in each single country. Lastly, 
most SMEs that develop adherence enhancing technology are usually based in one country, but aim to 
sell their products in multiple countries and therefore require a European wide network for optimal 
implementation of their technology. 
 
The existing efforts at the European and/or international level are outlined below. 
 
•  ESPACOMP: formally European, this is the only of its kind in the world scientific society that 
focuses on research and methods related to medication adherence. The audience is mainly 
academic and has limited involvement of SMEs and policy makers. The ENABLE Action aims 
for collaboration with ESPACOMP, which could play a potential role in knowledge dissemination 
and advocacy of ENABLE’s findings. 
•  ABC (FP7 project, ended in 2012): This was the first EU funded effort on standardizing 
adherence taxonomy and identification of current pitfalls in adherence research. Yet, this project 
was mostly performed before the adherence technology era. Still, this COST Action could built 
onto the knowledge that was gained in the ABC project. 
•  European Innovation Partnership on Active and Healthy Ageing (EIP-AHA): This is a very broad 
initiative aiming at health aging and who recently published the report “Blueprint on digital 
transformation of health and care for aging society”. Specifically the Action Plan A1 (Prescription 
and adherence action at regional level) and Plan B3 (Integrated Care) are of relevance in 
relation to this Action. 
•  Digital Single Market (European Commission): This project aims to tear down regulatory walls 
and moving from 28 national markets to a single one. The ENABLE vision fits perfectly with its 
focus on European wide implementation of adherence enhancing technology. 
•  EARIP & ASTROLAB (FP7 project, ongoing): both projects focus on asthma treatment issues 
and have adherence included as part of their objectives. While the focus is on asthma only, data 
may be of interest for ENABLE. 
•  International Society For Pharmacoeconomics and Outcomes Research Medication Adherence 
and Persistence Special Interest Group (ISPOR MAP): aims to stimulate research and 
evaluation on issues related to medication adherence, treatment persistence, and implications 
for health outcomes. ISPOR - the leading global professional society in pharmacoeconomics 
 
        10
and outcomes research - could assist with the dissemination of ENABLE’s findings to a broader 
audience. 
 
As compared to existing efforts outlined above, the ENABLE COST Action will have a unique and 
specific focus that goes beyond the objectives of the existing efforts. It will be disease and discipline 
overarching, is multidisciplinary (providers, patients, policy makers), incorporates the latest state-of-
the-art adherence enhancing technology through SME involvement and has a strong focus 
onsustainable, cost-effective implementation across Europe. 
2.2 ADDED VALUE OF NETWORKING IN IMPACT 
2.2.1 SECURING THE CRITICAL MASS AND EXPERTISE  
The ENABLE network has the mutual objective to accelerate the development, availability and 
sustainable implementation of adherence enhancing technologies in daily clinical practice. The ENABLE 
network agrees that multidisciplinary, pan-European and private-public networking is the best way to 
address current challenges. Notably, ENABLE network members will be selected because of their 
excellent complimentary expertise, reputation as well as relevant network in the field.  
 
The total pan-European network of collaborators will include healthcare professionals, researchers, 
policy makers, patient organizations and SMEs. The partners from Eastern and Western European 
countries have complimentary expertise on medical and pharmaceutical practice and sciences, 
nursing, engineering, health psychology, communication, implementation science, health economics 
and policy. Notably, many future collaborators are working on adherence-related issues on a daily basis, 
are leaders in their respective sub-fields and are represented in (or are on boards of) (inter)national 
academic/policy associations, guidelines and related national or international initiatives on adherence. 
Altogether, ENABLE will benefit from a multidisciplinary, well-balanced and impactful network that 
will maximize the chances that the critical mass and key stakeholders across Europe are reached and 
involved for successfully addressing the key challenges and objectives related to the global challenge 
of non-adherence to medication. 
 
The ENABLE Action plans also to involve and 
expand a critical mass of other essential 
stakeholders that can impact the 
implementation of adherence enhancing 
interventions immediately (e.g. by involving 
partners with high power and interest) and in 
the future (e.g. by also involving ECIs). For 
stakeholder selection and management a 
Power/Interest grid (Figure 2), will be 
created for each country within ENABLE. 
 
Figure 2: Stakeholder power/interest grid 
2.2.2 INVOLVEMENT OF STAKEHOLDERS 
Per country, around five representatives from clinical practice will be involved, such as healthcare 
professionals involved in enhancing adherence (physicians, pharmacists, psychologists & nurses), 
especially those involved in clinical guideline development or with a key position in national or European 
clinical societies. In addition, patient associations, informal care associations and regulators 
(registration authorities, payers and health insurance policy makers) from each country will be targeted 
through the existing networks of ENABLE Action participants but also by actively reaching out. Naturally, 
other main participants are the engineers that develop these technologies, mostly working in SMEs. 
Lastly, experts with specific expertise in e.g. communication and dissemination on a European level, 
such as participants involved in patient advocacy, will be asked to join the ENABLE Action. Stakeholder 
involvement will mainly be carried out through the networks of the Management Committee members 
in the ENABLE Action, centrally coordinated by the responsible Working Group (WG 1, see Figure 3). 
To maximize exposure, materials will become available in local languages and will take into account the 
level of information is also accessible for people with low literacy. 
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In addition, engagement with stakeholders will be created through (1) an overarching ENABLE website 
with aims, collaborators and news/blogs/vlogs, recent findings where also links to the local “medication 
adherence expertise centers” will be provided; (2) local adherence awareness events (preferably with 
media attention) surrounding the launch of the local expertise centers in each country; (3) establishment 
of national “Adherence Awareness Days”; (4) the first conference: to identify and actively invite key 
stakeholders and to create a roadmap with unmet research and policy needs; (5) stakeholder meetings 
linked to existing clinical/scientific conferences (e.g. ESPACOMP, EuroDURG, disease focused 
conferences): to network and disseminate knowledge to non-specialist audiences; (6) Short-Term 
Scientific Missions aiming to increase knowledge, awareness and  visibility; (7) editorials/call-for-
actions in scientific, clinical and policy oriented conferences and journals, as well as on online network 
platforms such as LinkedIn, Twitter and ResearchGate. 
2.2.3 MUTUAL BENEFITS OF THE INVOLVEMENT OF SECONDARY PROPOSERS FROM NEAR 
NEIGHBOUR OR INTERNATIONAL PARTNER COUNTRIES OR INTERNATIONAL 
ORGANISATIONS 
Given the initial focus on implementation of adherence enhancing technologies and strategies in the 
European healthcare systems, currently no Near Neighbour Countries are involved in the ENABLE 
Action. Yet, the Action will be open for their participation and, moreover, from the beginning they will be 
able to indirectly benefit from the deliverables of this Action, such as the freely accessible webplatform 
with demonstrations of innovation in digital technologies that can enhance medication adherence. 
International organisations are also not yet directly involved in this stage, but many future participants 
of this Action are actively involved in relevant international clinical, patient and policy organizations that 
could become collaborators for the Action. In particular, it is anticipated that these organisations could 
play a complimentary role in promotion, member expansion, knowledge dissemination and scale up of 
adherence interventions both inside and outside Europe. 
3 IMPACT 
3.1 IMPACT TO SCIENCE, SOCIETY AND COMPETITIVENESS, AND 
POTENTIAL FOR INNOVATION/BREAK-THROUGHS 
3.1.1 SCIENTIFIC, TECHNOLOGICAL, AND/OR SOCIOECONOMIC IMPACTS (INCLUDING 
POTENTIAL INNOVATIONS AND/OR BREAKTHROUGHS) 
ENABLE will tackle a highly relevant issue with substantial cross-sectorial impact. Systematic reviews 
indicate a wide-ranging negative impact of non-adherence, and reveal consistent associations of 
nonadherence to worse clinical (i.e. 200,000 deaths) as well as economic outcomes (i.e. €80-125 billion) 
across the full spectrum of chronic diseases. In current practice, suboptimal response to an initial drug 
is usually followed by the addition of a 2nd or 3rd drug without checking and optimizing adherence to 
the initial drug, leading to unnecessary side-effects and medication costs. For example in asthma, when 
patients are non-adherent to their regular inhaler (e.g. budesonide/formoterol, costing +/-€500 annually) 
and this is not checked and optimized, physicians may assume the drug is not working sufficiently and 
may subsequently prescribe a more invasive and expensive biological drug (e.g. mepolizumab, costing 
€15,000 annually). In 2005, a systematic review on adherence enhancing interventions already 
indicated that “improving adherence seems to be fairly low on the policy agenda, but better use of 
existing drugs is likely to be more cost-effective than many new drugs”.10 Despite efforts to address the 
issue, a large study published in 2015 across Europe that compared ten national - adherence policies 
concluded that implementation of medication adherence policy solutions had failed.6 Furthermore, the 
most recent epidemiological studies on medication adherence continue to indicate consistently low 
adherence rates, highlighting the potential impact of innovative implementation strategies focusing on 
proper medication use. Given the above, it is anticipated that ENABLE could have scientific, 
technological and/or socioeconomic impacts and has potential for innovation as further detailed below. 
 
Short term impact 
 
In the short-term, several important scientific and technological impacts are anticipated due to 
increased multidisciplinary and private-public collaboration on medication adherence. These include:  
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(1) The establishment of an interdisciplinary pan-European network of stakeholders that develops, 
assesses and works with adherence enhancing technology and exchanges this knowledge within and 
beyond the network itself 
 
(2) Increased awareness about non-adherence among the network’s internal and external stakeholders 
 
(3) Increased visibility and benchmarking of novel adherence enhancing solutions, to identify the 
most promising ones, worth scaling up 
 
(4) Engagement and training of PhD students and ECIs in a highly multidisciplinary environment (e.g. 
by offering STSMs at SMEs, regulators or labs of experienced investigators in other countries), 
preparing them to become the next generation of highly creative and skilled researchers 
 
(5) Dissemination of implementation strategies for healthcare professionals, patients, decision makers 
and SMEs across Europe and the world, by means of development of an interactive and freely 
accessible web platform, and 
 
(6) Advocating for broad implementation and reimbursement of cutting-edge technologies of 
adherence management to the benefit of all stakeholders. 
 
Long term impact 
 
In the long-term, ENABLE envisages significant clinical, economic and technological impact which will 
foster healthy ageing and contribute to sustainable and equitable healthcare systems. Three forms 
of impact have been identified. 
 
(1) Technological impact: once clinical and behavioural context, pathways to patient access and 
reimbursement are clear, more SMEs will invest in tailored medical devices thereby accelerating 
innovation 
 
(2) Clinical impact: patients and providers will have better awareness and earlier and easier access to 
new technology. Uptake of adherence enhancing technology in clinical guidelines could further stimulate 
its use, implementation and beneficial effects. Ultimately, this could lead to fewer medical complications, 
hospitalizations, a more efficient use of medication, lower mortality rates and better quality of life 
 
(3) Economic impact: fewer complications and more efficient use of medication will lead to lower 
healthcare costs and more work productivity. In addition, due to positive stimulation of European SMEs, 




Engineers are brilliant at designing technology, but in the case of medical technology they will also have 
to take into account medical professionals’ and patients’ knowledge, preferences and habits as ell as 
the challenging differential healthcare markets and systems across Europe. The ENABLE Action will 
allow innovative medical technology, aimed at enhancing medication adherence, to be readily 
applicable in real-world clinical practice and will find their way to patients and providers more efficiently. 
Through the shared development of new processes, patients and providers are allowed earlier access 
to innovative medical technology and practical guidance on adherence management. 
 
Currently, many innovators and investors in medical technology are held back by the opaque healthcare 
systems across Europe, which hampers realistic sales projections and further technological advances. 
Notably, the healthcare market is not a traditional seller-buyer market in the sense that the client is not 
always choosing the technology (the healthcare provider does) and is also not always paying it (in full) 
(health insurance does, partly). In particular, many of the current adherence enhancing technologies 
show potential in small-scale research settings and labs, but unfortunately never make it to the patient 
and market because of a lack of clinical relevance or lack of large-scale investments. The network 
created through ENABLE will require an initial effort from the ENABLE collaborators to bring together 
and activate the right stakeholders that are able to initiate a new technology implementation process. 
Challenges are envisaged in the process of convincing national policy makers and urging them to shift 
their focus from national to a pan-European view. Though there is a risk that policy makers do not want 
to broaden their views beyond national policy, it is anticipated 
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that the activities of ENABLE will create new incentives by leading to scientific breakthroughs by 
bringing innovating engineers, healthcare professionals and policy makers together resulting in 
crossfertilization and the generation of new scientific concepts and processes consisting of state-of-the-
art technology that is ready for wide use in current European medical and pharmaceutical practice. 
Concretely, this would lead to: 
 
(1)   patient and provider tailored adherence enhancing technology and 
(2) country-tailored implementation and reimbursement strategies for the adherence enhancing 
technologies. 
 
Information generated and disseminated through the ENABLE Action will stimulate SMEs and investors 
even more to develop medical technology (technological impact), being guided by easily accessible 
local medication adherence expertise centers and a pan-European web platform that help them to reach 
their end-users and give them a better and more transparent idea of their potential European market 
share. As a result of more practical guidance on adherence strategies, patients’ adherence will improve 
resulting in avoidance of unnecessary add-on medication and related side– effects and thus generates 
socioeconomic impact. 
3.2 MEASURES TO MAXIMISE IMPACT 
3.2.1 KNOWLEDGE CREATION, TRANSFER OF KNOWLEDGE AND CAREER DEVELOPMENT 
Knowledge creation 
 
By bringing together innovating engineers, healthcare professionals and policy makers new scientific 
concepts and processes regarding medication adherence technologies will be created. The open and 
multidisciplinary environment of ENABLE support cross fertilization and out-of-the-box ideas. At the 
same time, major challenges regarding implementation of medical adherence enhancing technology will 
be jointly tackled. This could result in technology that is provider and patient friendly and ready for wide 
use in current European medical and pharmaceutical practice. As such, this is expected to lead to better 
knowledge on (1) patient and provider tailored adherence enhancing technology and (2) country-tailored 
implementation and reimbursement strategies and early access pathways for adherence enhancing 
technologies. 
 
Transfer of knowledge 
 
Dissemination targets specific to the domain (professional publications, conferences for health 
profesionnals) and social media for patients will be identified in advance. Part of the knowledge transfer 
will be through existing clinical and patient associations, but also a list with abstract submission dates 
for key pre-identified conferences will be created, and in addition social and mass media (e.g. Twitter, 
LinkedIn) will be used. To reach the widest audience possible the aim is to publish the ENABLE Action’s 
findings exclusively in open access journals, thereby allowing access to knowledge without payment 
required. More detailed dissemination plans are outlined in section 3.2.2. 
 
When successfully established, the knowledge on optimal implementation of adherence technologies 
created through the ENABLE Action network may also serve as a blueprint for other medical 
technologies, such as diagnostic devices, pharmacogenetics or point-of-care tests seeking access to 




In WG2 (see also section 4.1.1), special emphasis is placed on the development of the careers of 
ECIs. Whenever possible the Management Committee will consider for leadership positions ECIs who 
will have a unique opportunity to develop their scientific skills as well as management and networking 
skills that will be to be invaluable for their future careers. Through the STSMs, ECIs can learn from 
senior investigators and policy makers on the use and regulations of technology in other countries. 
Alternatively, they can learn directly from engineers at SMEs that are developing these adherence 
enhancing technologies or from regulatory policy makers that are assessing these technologies. At the 
same time, the young investigators’ academic and/or clinical experience and country specific knowledge 
could benefit the SMEs in further optimizing their technologies to make them fit for purpose.  
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Beyond organizing and attending scientific missions, ECIs will be asked to contribute to the Action by 
providing content for the COST Action ENABLE platform. Technology oriented STSMs will take place 
between SMEs, investigators and end-user associations to learn about the practicalities and potential 
of new adherence enhancing technologies in clinical practice. 
3.2.2 PLAN FOR DISSEMINATION AND/OR EXPLOITATION AND DIALOGUE WITH THE 
GENERAL PUBLIC OR POLICY 
ENABLE will have a dedicated Working Group (WG) for dissemination and exploitation of the results 
(see section 4.1.1) to the scientific community, the professional and policy community as well as the 
general public. The WG will create a stakeholder platform and a detailed 4-year dissemination and 
communication plan based on the following strategies; 
 
(1) Stakeholder engagement: relevant stakeholders from the ENABLE countries (healthcare providers, 
patient associations, policy makers, SMEs) will be involved from an early stage onwards. They are 
essential in outlining the specific needs and contextual factors. To facilitate networking, the first 
conference will be organized in the first semester of year 2, followed by at least four smaller-scale face-
to-face meetings spread along the Action duration (at least one per year) supplemented by monthly 
web-meetings. 
 
(2) Professional societies and existing networks: the ENABLE Action network members are 
represented on many professional organizations on adherence, (primary) care and policy such as 
ESPACOMP, ISPE, EuroDURG, ISPOR, IPCRG, WONCA, and regulatory bodies. These organizations 
will serve as hubs for knowledge dissemination, raising awareness and ensuring knowledge is 
communicated and translated into clinical practice and reflected in policy. 
 
(3) Gold standard open access: to reach the widest audience possible the aim is to publish the 
ENABLE Action’s findings exclusively in open access journals, thereby allowing access to knowledge 
without payment required. 
 
(4) Searchable knowledge base: The ultimate goal here is the creation of an interactive European web 
platform that provides a state-of-the-art overview of available technology and specific guidance on 
implementing adherence enhancing solutions across European healthcare systems. The web platform 
is envisaged to be a large networking platform on adherence technology, freely accessible for healthcare 
providers, patients, policy makers and companies. 
 
(5) Engaging with the general public: Dissemination targets specific to the domain of the general 
public will be identified in advance. Part of the communication will be through traditional media channels 
and popular magazines, but in addition social and mass media (e.g. Twitter, LinkedIn) will be used. The 
Action aims for at least half-yearly updates. 
 
(6) Easily accessible local expertise centers: MC members will stimulate the set up of local/national 
Medication Adherence Expertise Centers where materials and trainings on effective application of 
adherence technologies and interventions in local language (also interpretable for people with low 
literacy) are available. 
4 IMPLEMENTATION 
4.1 COHERENCE AND EFFECTIVENESS OF THE WORK PLAN 
4.1.1 DESCRIPTION OF WORKING GROUPS, TASKS AND ACTIVITIES 
ENABLE has produced a detailed work plan describing all the Working Groups’ (WGs), tasks, activities, 
timeframes and deliverables in order to assure coherent and effective work of the entire network, and 
timely achievement of its objectives. In order to fulfil the objectives, the ENABLE Action includes four 
inter-related Working Groups (WGs) as depicted in Figure 3 and further described below. Each WG will 
have a WG Leader. The overall Action will be overseen by a Management Committee (MC), that will be 
support the WGs and guide the overall process to keep the Action on track. The Action MC will consist 
of up to two representatives for each COST Full or Cooperating Member.  
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Figure 3: Inter-relationships between Working Groups 
 
The Leaders of the four WGs will have a good gender balance (50/50) and each WG will consist of a 
mix of representatives from different scientific, age-group and European geographical areas, to allow a 
multidisciplinary and pan-European approach. At least two of the four Leaders of the WGs (50%) will be 
members from COST Inclusiveness Target Countries. 
 
WG 1: Current practices and unmet needs 
 
WG1 focusses on the identification of means through which non-adherence is dealt with by healthcare 
professionals working across all levels of the health care system in Europe (primary care, specialist 
care, pediatrics, pharmacy care, and nursing). In addition, best practices and successful adherence 
mamagement strategies in settings within and outside European systems will be identified. The ultimate 
goal for the WG is to ascertain unmet needs to improve medication adherence in European settings, in 
order to establish a call-for action. 
 
The COST networking tool used in this WG will be a stakeholder conference, with interactive break-out 
sessions in groups of max. 10 persons to stimulate participation and interactions. The conference will 
be attended by relevant stakeholders, with support from WG4. In order to collect necessary information 
on current practices and unmet needs, a survey will be disseminated to be completed by attendees prior 
to the conference and a report including (personal and health system) barriers and faciltators for 
medication adherence in each country will be drafted (D1.1). The final output of this Working Group will 
be a call-for-action (D1.2). The report and call for action will be published on the COST Action ENABLE 
platform. 
 
WG 1: Current practices and unmet needs 
Networking Tools Deliverables Related deliverables 
Conference  
Round table 
D1.1 Report of survey results 
D1.2 Call for action
D3.2 
 
WG 2: Adherence enhancing technologies 
 
The aim of WG2 is to publicly showcase an extensive range of adherence enhancing technology which 
is available in Europe (D2.1). This will be achieved through the facilitation of networking activities 
between SMEs and stakeholders in the healthcare setting, and through the organization of Short-Term 
Scientific Missions (STSMs) between researchers, SMEs, policy makers and end-user associations.  
 
Technology oriented STSMs will take place between SMEs, (early stage) investigators and end-user 
associations to learn about the practicalities and potential of new adherence enhancing technologies in 
clinical practice. In WG2, emphasis is placed on the development of ECIs. Beyond organizing and 
attending STSMs, ECIs will be stimulated to contribute to the Action by providing content for the 
ENABLE platform. This will include a digital report/database  with an overview of exisiting adherence 
enhancing technologies (D2.1). STSM participants will add a report with user and expert experiences to 
the technologies they have encountered (D2.2), in formats which can be uploaded on the COST Action 
ENABLE platform. The content could be supplemented by a blog and/or vlog to communicate and 
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disseminate their experiences and insights brought about by the STSMs. In order to ensure a wealth of 
information on adherence enhancing technologies on the ENABLE platform, members of the Action will 
attend relevant dissemination meetings and ask SMEs to provide additional information to upload on 
the platform, and organize a final “digital networking market” throughout the Action’s final conference, 
which will allow SMEs to showcase their products. 
 
WG 2: Adherence enhancing technologies 





D2.1 Online report/database with key 
adherence enhancing technologies 






WG 3: Sustainable implementation of adherence enhancing technologies 
 
The task of WG3 is to pave the way for adherence enhancing technology to be implemented in European 
health care settings. This will involve the sharing, collection and dissemination of information on 
European healthcare systems (e.g. division of clinical tasks and responsibilities between primary care 
and secondary care as well as access to care) (D3.1), contact information of key stakeholder 
associations (D3.2) and reimbursement pathways/HTA guidelines (D3.3) for new adherence enhancing 
technologies. Existing databases with relevant information, e.g. The Health Systems and Policy Monitor, 
and information on health system barriers and facilitators (D1.1) collected in WG1 will be consulted to 
avoid a duplication of efforts. Collected information will be publicly disseminated by means of the 
ENABLE platform.  
 
In addition to the collection and dissemination of information, policy oriented STSMs will be organized 
to facilitate an exchange of knowledge between healthcare policy makers and providers of technologies. 
STSMs in WG3 will focus particularly on the regulatory aspects involved in the implementation and use 
of adherence enhancing technologies in countries throughout Europe.  
 
Information on national policies and guidelines affecting the implementation of adherence enhancing 
technologies, will be collected through reports about STSMs in different member states, WG meetings 
during which guest speakers will be invited to speak about the aforementioned issues, and through 
using existing information/data which will be uploaded to the ENABLE platform by WG4. 
 
WG 3: Sustainable implementation of adherence enhancing technologies 
Networking Tools Deliverables Related deliverables 






D3.1 Overview European 
healthcare systems (report) 
D3.2 Overview of organizations 
of key stakeholders (report)  
D3.3 Overview of 
reimbursement pathways for 
new adherence enhancing 
technologies (report)
D1.1, D4.1   
 
WG 4: Communication and Dissemination 
 
The goal of WG4 is to disseminate and exploit the knowledge collected throughout activities in WG1, 
WG2, and WG3, and to ensure the active representation of all relevant stakeholders throughout the 
Action. The WG will do so through the development and maintenance of the COST ENABLE 
webplatform (D4.1) through which information will be publicly disseminated. Alongside this, WG4 will 
develop and carry out a communication plan (D4.2) with innovative tools to reach critical mass (incl. 
SMEs, professionals, policy makers, patients and the public). In line with this, WG4 also plays a key role 
in the mobilization of stakeholders to participate and contribute to the Action and the knowledge base. 
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WG 4: Communication and Dissemination 
Networking Tools Deliverables Related deliverables 
WG meetings D4.1 Development of Action 
website (COST Action 
ENABLE Platform) 
D4.2 Communication plan
D1.2, D2.1, D2.2,  
D3.1, D3.2, D3.3  
4.1.2 DESCRIPTION OF DELIVERABLES AND TIMEFRAME 
The deliverables related to the WGs are presented in the tables in section 4.1.1 and the anticipated 
timeframe is presented in the GANTT diagram in section 4.1.4. The total timeframe is 4 years. The 
organisation of ENABLE will conform to the "Rules and Procedures for implementing COST Actions". 
4.1.3 RISK ANALYSIS AND CONTINGENCY PLANS 
Risk of insufficient quality: ENABLE delivers poor quality findings. ENABLE will have a strict quality 
management system to ensure that all findings and deliverables are of the highest quality. The quality 
management system consists of reviews by at least two MC members of the Action (internal quality 
control), and external experts as reviewers of public meetings and journals as part of the dissemination 
process (external quality control). If any ENABLE deliverable fails to meet the highest possible quality 
standard it will be returned to the responsible party for revision. Importantly, the participants will not 
operate alone. If a product is sent back for revision, the reviewers and external experts will provide 
detailed comments and discuss the quality problems with the authors in order to improve the product. 
 
Risk of delays: ENABLE deliverables cannot be submitted in time. ENABLE will aim to use a set of 
management software (e.g. SharePoint or Teamwork) to help minimize the risk of delays. At the first 
indication of a delay, the MC will discuss and develop a risk mitigation strategy. Key mitigation 
approaches will include: devoting extra resources to the task; running sequential tasks in parallel to 
avoid delays, and developing plans for reducing time needed to complete follow-on tasks. In some cases 
these strategies will involve revising ENABLE’s internal schedule, but should not affect the overall 
delivery schedule. Finally, it should be noted that the Action’s transparent and comprehensive 
communications process will help to identify and address any possible delays expeditiously. 
 
Risk of cost overruns: ENABLE costs will be beyond the awarded budget. In the case of cost overruns, 
the Action will not ask for additional funding although it may ask for permission to adjust some aspects 
of the ENABLE activities (e.g. invitation of fewer particiapants to attend workshops and dissemination 
events). Unforeseen risks may require that participants will contribute additional in-kind resources (e.g. 
staff time) to ensure successful completion of the ENABLE’s objectives, i.e. the network will complete 
the outlined scope within the budget. 
 
Personnel leaving risk: Key personnel become unavailable to complete ENABLE. In the instance that 
one or more key personnel will leave ENABLE before the end of the Action, members will try to find a 
suitable replacement (or equivalent expertise) and seek approval for the replacement from the Action 
MC. A key strength of ENABLE, however, is that each of the particiapnts is expected to have several 
staff members who could successfully complete the organisations’ allocated responsibilities, meaning 
staff changes should result in minimal loss of knowledge, or have minimal impact on ENABLE overall. 
 
Risk of breach by a party of its obligations or responsibilities: The amount or quality of work 
provided by a participant does not comply with expectations or obligations. The relevant participant will 
be informed by the MC about the problem and its impact on the overall ENABLE Action and their need 
for performance improvements. If the participant fails to respond positively, appropriate measures will 
be taken by the MC.  
 
Risk of collecting insufficient basic data: to minimise the risk of capturing insufficient data to enable 
the development of consensus recommendations, the network will be strategically built to ensure a wide 
range of particiapant from Eastern and Western European countries. Moreover, each collaborating 
particiapant also has a wider network of relevant stakeholders and contacts that can be called upon, 
should there be need. 
 
Risk of insufficient extent of dissemination: ENABLE information does not reach the intended target 
audience. First, ENABLE will utilize a wide variety of communication channels including the internet, 
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technical publications, public events, conferences, newspaper articles and videos. ENABLE participants 
will have extensive experience in the dissemination of technical research results and in communication 
of complex research ideas to colleagues, external parities and the general public. Thus, the use of a 
wide range of media channels and expert collaborators in the dissemination of ENABLE will ensure the 
results reach the largest possible target audience. 
4.1.4 GANTT DIAGRAM 
The Gantt diagram can be found in Table 1.  
Table 1: Gantt diagram of the ENABLE COST Action 
WP Tool (T) / Deliverable (D) / milestone (M) Y1-S1 Y1-S2 Y2-S1 Y2-S2 Y3-S1 Y3-S2 Y4-S1 Y4-S2 
N/A T1: First MC meeting         
N/A T2: Second MC meeting with First Conference (open event)         
N/A T3: Third MC meeting         
N/A T4: Fourth MC meeting and Final Conference (open event)         
1  D1.1 Survey results (report)  D1.1       
1  D1.2 Call for action    D1.2     
1 M1. Call for action signed and submitted    M1     
2 T5: Short-Term Scientific Missions (Technology oriented)         
2 T6: Digital Networking Market (Conference)         
2  D2.1 Descriptions of key adherence enhancing 
technologies 
  D2.1.1  D2.1.2  D2.1.3 D2.1.4 
2  D2.2 Report with review of adherence enhancing 
technology 
  D2.2.1  D2.2.2  D2.2.3 D2.2.4 
2 M2. Call for STSMs (technology oriented) posted  M2 M2  M2  M2  
2 T7: Attending Dissemination meetings          
3 T8: WG Meetings          
3 T9: Short-Term Scientific Missions (Policy oriented)         
3  D3.1 Overview European healthcare systems (report)     D3.1    
3  D3.2 Overview of organizations of key stakeholders  
(report) 
    D3.2    
3  D3.3 Overview of reimbursement pathways for new 
adherence enhancing technologies (report) 
    D3.3    
3 M3. Call for STSMs (policy oriented) posted  M3 M3  M3  M3  
4 T10: WG Meeting         
4  D4.1 Development of Action website  D4.1       
4  D4.2 Communication plan  D4.2       
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